Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived stromal vascular fraction cells
- Development stage
- Unknown
- Lead developer
- Michael H Carstens
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Autologous adipose-derived stromal vascular fraction (SVF) cells represent a heterogeneous population of cells obtained from a patient's own lipoaspirate. This fraction contains a mixture of adipose-derived stem cells (ADSCs), endothelial precursor cells, pericytes, and various immune cells. When used for the treatment of knee osteoarthritis, the SVF is typically isolated at the point of care and administered via intra-articular injection. The therapeutic mechanism is primarily paracrine, where the cells secrete a variety of anti-inflammatory cytokines and growth factors that modulate the joint environment, reduce chronic inflammation, and potentially promote the regeneration or protection of articular cartilage. Clinical studies led by Michael H Carstens have evaluated this therapy in patients with Kellgren-Lawrence Grade 3 knee osteoarthritis, demonstrating long-term safety and clinical response over follow-up periods as long as ten years.
- Other names
- autologous adipose tissue-derived stromal vascular fraction cellsSVF cellsadipose-derived stromal vascular fraction
Beyond the preview
Go deeper on autologous adipose-derived stromal vascular fraction cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived stromal vascular fraction cells.